Trial Profile
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Transplant Recipients Who Developed Antibody Mediated Rejection (ABMR) including Patients With Donor Specific Antibody (DSA) Resistant to Intravenous Immunoglobulin (IVIG) + Rituxan Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2015 New trial record